OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Diagnosis and Treatment of Chronic Lymphocytic Leukemia
Mazyar Shadman
JAMA (2023) Vol. 329, Iss. 11, pp. 918-918
Closed Access | Times Cited: 118
Mazyar Shadman
JAMA (2023) Vol. 329, Iss. 11, pp. 918-918
Closed Access | Times Cited: 118
Showing 1-25 of 118 citing articles:
Causes and consequences of clonal hematopoiesis
Lachelle D. Weeks, Benjamin L. Ebert
Blood (2023) Vol. 142, Iss. 26, pp. 2235-2246
Open Access | Times Cited: 50
Lachelle D. Weeks, Benjamin L. Ebert
Blood (2023) Vol. 142, Iss. 26, pp. 2235-2246
Open Access | Times Cited: 50
Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study
Othman Al‐Sawaf, Sandra Robrecht, Can Zhang, et al.
Blood (2024) Vol. 144, Iss. 18, pp. 1924-1935
Open Access | Times Cited: 29
Othman Al‐Sawaf, Sandra Robrecht, Can Zhang, et al.
Blood (2024) Vol. 144, Iss. 18, pp. 1924-1935
Open Access | Times Cited: 29
Spleen-targeted delivery systems and strategies for spleen-related diseases
Ziyao Huang, Kedong Sun, Zhenyu Luo, et al.
Journal of Controlled Release (2024) Vol. 370, pp. 773-797
Closed Access | Times Cited: 14
Ziyao Huang, Kedong Sun, Zhenyu Luo, et al.
Journal of Controlled Release (2024) Vol. 370, pp. 773-797
Closed Access | Times Cited: 14
Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms
Samir Mouhssine, Nawar Maher, Bassam Francis Matti, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3234-3234
Open Access | Times Cited: 13
Samir Mouhssine, Nawar Maher, Bassam Francis Matti, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3234-3234
Open Access | Times Cited: 13
Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers
Nawar Maher, Samir Mouhssine, Bassam Francis Matti, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10374-10374
Open Access | Times Cited: 18
Nawar Maher, Samir Mouhssine, Bassam Francis Matti, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10374-10374
Open Access | Times Cited: 18
Disulfide Cross-Linked Polymeric Redox-Responsive Nanocarrier Based on Heparin, Chitosan and Lipoic Acid Improved Drug Accumulation, Increased Cytotoxicity and Selectivity to Leukemia Cells by Tumor Targeting via “Aikido” Principle
Igor D. Zlotnikov, Alexander A. Ezhov, Natalia V. Dobryakova, et al.
Gels (2024) Vol. 10, Iss. 3, pp. 157-157
Open Access | Times Cited: 7
Igor D. Zlotnikov, Alexander A. Ezhov, Natalia V. Dobryakova, et al.
Gels (2024) Vol. 10, Iss. 3, pp. 157-157
Open Access | Times Cited: 7
Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening
Xing Li, Shiyu Sun, Wansong Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 7
Xing Li, Shiyu Sun, Wansong Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 7
Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed/Refractory CLL: Phase 1b BRUIN Trial
Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, et al.
Blood (2024) Vol. 144, Iss. 13, pp. 1374-1386
Closed Access | Times Cited: 7
Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, et al.
Blood (2024) Vol. 144, Iss. 13, pp. 1374-1386
Closed Access | Times Cited: 7
Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints
Stefano Molica
Expert Review of Hematology (2024) Vol. 17, Iss. 7, pp. 279-285
Open Access | Times Cited: 5
Stefano Molica
Expert Review of Hematology (2024) Vol. 17, Iss. 7, pp. 279-285
Open Access | Times Cited: 5
Histone deacetylase inhibitors for leukemia treatment: current status and future directions
Mohammad‐Salar Hosseini, Zohreh Sanaat, Mohammad Amin Akbarzadeh, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 5
Mohammad‐Salar Hosseini, Zohreh Sanaat, Mohammad Amin Akbarzadeh, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 5
Nanodelivery Systems as a Novel Strategy to Overcome Treatment Failure of Cancer
He Shi, Xinyu Gou, Shuheng Zhang, et al.
Small Methods (2023) Vol. 8, Iss. 1
Closed Access | Times Cited: 10
He Shi, Xinyu Gou, Shuheng Zhang, et al.
Small Methods (2023) Vol. 8, Iss. 1
Closed Access | Times Cited: 10
Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the 1st Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
Alexey V. Danilov, Craig S. Sauter, Tycel Phillips, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Alexey V. Danilov, Craig S. Sauter, Tycel Phillips, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders
Franz Felix Konen, Nora Möhn, Torsten Witte, et al.
Autoimmunity Reviews (2025) Vol. 24, Iss. 4, pp. 103754-103754
Closed Access
Franz Felix Konen, Nora Möhn, Torsten Witte, et al.
Autoimmunity Reviews (2025) Vol. 24, Iss. 4, pp. 103754-103754
Closed Access
Flow cytometry immunophenotyping in diagnosed cases of B-cell chronic lymphoproliferative disorders
Balasuriya Lekamlage Thushara Balasuriya, C. S. Moonesinghe, Neluka Fernando, et al.
(2025) Vol. 1, pp. 6-14
Closed Access
Balasuriya Lekamlage Thushara Balasuriya, C. S. Moonesinghe, Neluka Fernando, et al.
(2025) Vol. 1, pp. 6-14
Closed Access
Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
Fuli Fan, Xiaodan Liu, Zhan Su, et al.
Hematological Oncology (2025) Vol. 43, Iss. 2
Closed Access
Fuli Fan, Xiaodan Liu, Zhan Su, et al.
Hematological Oncology (2025) Vol. 43, Iss. 2
Closed Access
The Heterogeneity of 13q Deletions in Chronic Lymphocytic Leukemia: Diagnostic Challenges and Clinical Implications
Chang‐Qing Xia, Guang Liu, Jinglan Liu, et al.
Genes (2025) Vol. 16, Iss. 3, pp. 252-252
Open Access
Chang‐Qing Xia, Guang Liu, Jinglan Liu, et al.
Genes (2025) Vol. 16, Iss. 3, pp. 252-252
Open Access
Evidence-based investigation of the efficacy and safety of venetoclax-containing regimens versus chemoimmunotherapy in chronic lymphocytic leukemia
Pu Yao, Jiao Zhang, Xiaowen Wang, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Pu Yao, Jiao Zhang, Xiaowen Wang, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review
David B. Miklos, Peter A. Riedell, Alex Bokun, et al.
Targeted Oncology (2025)
Open Access
David B. Miklos, Peter A. Riedell, Alex Bokun, et al.
Targeted Oncology (2025)
Open Access
An Incidental Finding of Gain of a Diminished Chromosome 12 Centromere in an Individual with Lymphocytosis: A Case Report and Clinical Implications in Cytogenetic Testing
Chang‐Qing Xia, Jeffrey J. Cannatella, Scott C. Smith, et al.
Diagnostics (2025) Vol. 15, Iss. 5, pp. 618-618
Open Access
Chang‐Qing Xia, Jeffrey J. Cannatella, Scott C. Smith, et al.
Diagnostics (2025) Vol. 15, Iss. 5, pp. 618-618
Open Access
Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies
Nawar Maher, Samir Mouhssine, Bassam Francis Matti, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 907-907
Open Access
Nawar Maher, Samir Mouhssine, Bassam Francis Matti, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 907-907
Open Access
Effects of a strength physical exercise program in chronic lymphocytic leukemia patients on quality of life, mental health, and frailty: a randomized controlled trial study protocol
Juan Luis Sánchez-González, Eduardo José Fernández Rodríguez, Roberto Méndez‐Sánchez, et al.
Frontiers in Sports and Active Living (2025) Vol. 7
Open Access
Juan Luis Sánchez-González, Eduardo José Fernández Rodríguez, Roberto Méndez‐Sánchez, et al.
Frontiers in Sports and Active Living (2025) Vol. 7
Open Access
Consensus in CLL: global needs matter
Mazyar Shadman, Bita Fakhri, Nitin Jain
Blood Advances (2025) Vol. 9, Iss. 5, pp. 1210-1212
Open Access
Mazyar Shadman, Bita Fakhri, Nitin Jain
Blood Advances (2025) Vol. 9, Iss. 5, pp. 1210-1212
Open Access
Chronic Lymphocytic Leukemia: Investigation of Survival and Prognostic Factors with Drug-Related Remission
Gökhan Pektaş, Ercan Gönül, Şeyma Öncü, et al.
Diagnostics (2025) Vol. 15, Iss. 6, pp. 728-728
Open Access
Gökhan Pektaş, Ercan Gönül, Şeyma Öncü, et al.
Diagnostics (2025) Vol. 15, Iss. 6, pp. 728-728
Open Access
Developing a simple clinical risk score for ibrutinib-associated atrial fibrillation
Tyler Jacobson, Graham Peigh, Ruchi Patel, et al.
Journal of Interventional Cardiac Electrophysiology (2025)
Closed Access
Tyler Jacobson, Graham Peigh, Ruchi Patel, et al.
Journal of Interventional Cardiac Electrophysiology (2025)
Closed Access
Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report
Arina Martynchyk, Cameron Wellard, Eliza Chung, et al.
Internal Medicine Journal (2025)
Closed Access
Arina Martynchyk, Cameron Wellard, Eliza Chung, et al.
Internal Medicine Journal (2025)
Closed Access
